Remedium is a biotechnology company using in-silico chemistry for drug design through artificial intelligence. The company was founded in 2017 in Montreal, Quebec, Canada.
The company has created a platform for artificial intelligence-based innovations for drug design. The platform is a structural bioinformatics software platform that utilizes machine learning techniques capable of analyzing any protein with known or suspected therapeutic value accurately. Remedium looks to have their platform provide solutions faster than conventional strategies in order to reduce development costs associated with traditional drug discovery methods.
The Remedium team has published analyses of early prototypes of computational methodologies including transient protein-protein interface prediction, and algorithmic approaches to protein-protein interaction site prediction. The company has implemented formulations for protein-based drugs, and is interesting in igniting a paradigm shift in pharmaceutical drug discovery.
